- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Endoglin (ENG), also known as CD105, is a transmembrane glycoprotein expressed on endothelial cells, where it functions as a key regulator of angiogenesis and vascular signaling. CD105 Antibody / Microarray Specificity Validated Antibody (clone ENG/3269) targets this protein and provides highly specific detection supported by protein microarray validation. CD105 antibody, also referred to as Endoglin antibody and ENG antibody in the literature, detects an endothelial marker widely used in studies of vascular development and tumor-associated angiogenesis.
Functionally, Endoglin participates in TGF-beta signaling pathways that regulate endothelial cell proliferation, migration, and differentiation. It acts as a co-receptor for TGF-beta ligands and contributes to vascular remodeling and repair. CD105 expression is particularly elevated in actively proliferating endothelial cells, especially within tumor vasculature, where it serves as a marker of angiogenic activity and neovascularization.
Expression of CD105 is most prominent in endothelial cells lining blood vessels, with increased levels observed in newly formed vessels and areas of active angiogenesis. In tumor tissues, CD105-positive endothelial cells are frequently found within the tumor microenvironment, reflecting enhanced vascularization. The ENG gene is located on chromosome 9q34.11 and plays a critical role in maintaining vascular integrity, with mutations linked to hereditary hemorrhagic telangiectasia.
Structurally, Endoglin is a homodimeric membrane protein composed of an extracellular ligand-binding domain, a transmembrane region, and a cytoplasmic tail that mediates intracellular signaling. It interacts with components of the TGF-beta receptor complex and influences downstream signaling pathways that regulate endothelial cell function. Endoglin may also co-localize with other vascular markers involved in angiogenesis and endothelial signaling.
Protein microarray validation demonstrates strong and specific binding of this antibody to CD105 with minimal off-target interaction, supporting reliable detection of Endoglin in complex protein samples. This high level of specificity is particularly valuable in applications requiring precise target recognition, such as comparative expression analysis and validation studies.
Altered CD105 expression is associated with cancer progression, vascular disease, and inflammatory responses, where dysregulated angiogenesis plays a central role. In oncology, elevated Endoglin expression correlates with tumor growth and metastasis, reflecting increased vascularization. In inflammatory and repair processes, CD105-positive endothelial cells contribute to tissue regeneration and immune cell trafficking.
This antibody provides highly specific detection of CD105 / Endoglin supported by protein microarray validation, making it suitable for research applications requiring confident identification of this endothelial marker. A CD105 antibody is suitable for detecting this angiogenesis-associated protein in studies of vascular biology, tumor angiogenesis, and endothelial cell function. For broader detection of CD105 as an endothelial marker across applications, see our CD105 antibody.
Optimal dilution of the CD105 Antibody / Microarray Specificity Validated Antibody should be determined by the researcher.
A partial recombinant protein corresponding to amino acids 74-251 of human CD105/Endoglin was used as the immunogen for the CD105 antibody.
Store the CD105 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Endoglin antibody, ENG antibody, CD105 microarray antibody, Endoglin validated antibody, ENG specificity antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.